Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Sep;78(3):696-702.
doi: 10.1172/JCI112629.

Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation

Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation

M E Hemler et al. J Clin Invest. 1986 Sep.

Abstract

Lymphocytes from the synovial fluid of eight out of eight rheumatoid arthritis (RA) patients had elevated very late activation antigen-1 (VLA-1) expression (10-36% positive cells), whereas peripheral blood lymphocytes (PBL) from RA patients and healthy controls had low VLA-1 expression (0-6% positive cells). During 1-2 wk of in vitro culture, VLA-1 increased on synovial fluid cells but remained low on PBL. In comparison, the interleukin 2 receptor (IL-2 R) was less prominent than VLA-1 on fresh synovial fluid cells, did not increase on cultured synovial fluid T cells, but did increase greatly on cultured PBL. The mitogen PHA reversed or prevented the appearance of VLA-1+, IL-2 R- synovial fluid cells during in vitro culture, thus giving IL-2 R+, VLA-1- cells. These results emphasize that VLA-1+ SF cells are different from resting cells or IL-2 R+ activated PBL T cells, and VLA-1 on synovial fluid T cells may be incompatible with mitogen stimulation. In addition, the VLA-2 heterodimer (165,000/130,000 relative molecular mass [Mr]) was regulated opposite to the VLA-1 heterodimer (130,000/210,000 Mr) on synovial lymphocytes, and thus the VLA-1/VLA-2 ratio is another indicator of the stage of T cell activation.

PubMed Disclaimer

References

    1. Immunology. 1973 Nov;25(5):905-8 - PubMed
    1. Bull Rheum Dis. 1958 Dec;9(4):175-6 - PubMed
    1. J Immunol. 1979 Oct;123(4):1548-50 - PubMed
    1. J Exp Med. 1980 Jan 1;151(1):91-100 - PubMed
    1. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6134-8 - PubMed

Publication types

MeSH terms

Substances